Heart Failure Management: Current and Future Challenges
Cardiology
Curriculum:
Current and Emerging Treatment Options for Patients with Chronic Heart Failure
Current and Emerging Treatment Options for Patients with Chronic Heart Failure
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
October 01, 2015
October 01, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Cardiologists, Primary Care Physicians, Hospitalists, Internal Medicine Physicians
Relevant Terms:
chronic heart failure, heart failure
Barry Greenberg, MD
Barry Greenberg, MD
Distinguished Professor of Medicine, Director
Advanced Heart Failure Treatment Program
Department of Medicine/Cardiology
University of California, San Diego
San Diego, CA
Bio
Dr. Greenberg, director of the Advanced Heart Failure Treatment Program, is a leading cardiologist specializing in heart failure. He is a founding member and past president of the Heart Failure Society of America (HFSA). He has been consistently selected as one of the "Best Doctors in America" since 1995.
Dr. Greenberg has been working in cardiology since 1971, including positions at the National Heart, Lung and Blood Institute (NHLBI), Oregon Health Sciences University, Royal Postgraduate Medical College, Hammersmith Hospital in London, and College de France in Paris.
Dr. Greenberg has been at UC San Diego since 1995, and is currently Professor of Medicine at UC San Diego School of Medicine and Director, Advanced Heart Failure Treatment Program at UC San Diego.
In addition to his clinical activities, Dr. Greenberg leads an active research program investigating basic mechanisms involved in heart failure and the development of new drugs and strategies to treat patients with this condition. He serves on the editorial boards of numerous cardiology journals and is an associate editor of the Journal of the American College of Cardiology.
Dr. Greenberg considers it a great privilege to get to know and help his patients and their families.
Javed Butler, MD MPH FACC FAHA
Javed Butler, MD MPH FACC FAHA
Chief of Cardiology
Co-Director, Heart Institute
Professor of Medicine
Stony Brook University
Stony Brook, NY
Bio
Dr. Butler is the chief of cardiology and co-director of the heart institute at the Stony Brook University. He is board certified in internal medicine, cardiovascular medicine, and advanced heart failure and transplant medicine. Prior to joining Stony Brook, he was professor of medicine at the Emory University. Dr. Butler has published over 220 peer-reviewed publications. Dr. Butler is the recipient of the Simon Dack Award by the American College of Cardiology and the Time, Feeling, and Focus award by the American Heart Association. He has been cited in America's Best Doctors numerous times. He serves on the ACC/AHA heart failure guidelines committee, on several NIH study sections, chairs the NIH heart failure network's ancillary studies committee; and he is a member of the executive council of the Heart Failure Society of America. He serves on the editorial board of several peer reviewed cardiovascular journals.
After completing his residency at Yale, cardiology fellowship and advanced heart failure and transplant fellowship at Vanderbilt, and cardiac imaging fellowship from the Massachusetts General Hospital. Prior to joining Emory, he served as the director of the cardiac and heart-lung transplant programs at Vanderbilt. He has completed Masters degree in Public Health from Harvard University and is currently pursing Masters in Business Administration from Emory University.
| 1. | Describe the epidemiology of heart failure (HF) , including the risk factors and associated clinical consequences. | 2. | Describe the pathophysiology of patients with systolic heart failure. |
| 3. | Implement current optimal medical therapy for the treatment of chronic congestive heart failure | 4. | Discuss the role of vasoactive peptides in the regulation of the cardiovascular system |
| 5. | Assess current data and potential role of new and emerging therapies for the treatment of heart failure with reduced ejection fraction |
| 1. | Describe the epidemiology of heart failure (HF) , including the risk factors and associated clinical consequences. |
| 2. | Describe the pathophysiology of patients with systolic heart failure. |
| 3. | Implement current optimal medical therapy for the treatment of chronic congestive heart failure |
| 4. | Discuss the role of vasoactive peptides in the regulation of the cardiovascular system |
| 5. | Assess current data and potential role of new and emerging therapies for the treatment of heart failure with reduced ejection fraction |
LAUNCH DATE/EXPIRATION DATE
This activity was launched on October 1, 2015 and will expire on October 1, 2016.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with heart failure.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with heart failure.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Barry Greenberg, MD | Dr. Greenberg has served as a consultant for Novartis, Teva, and Johnson and Johnson. |
| Javed Butler, MD, MPH, FAHA, FACC | Dr. Butler has been a consult for Amgen, Bayer, Cardiocell, Celladon, Jannsen, Novartis, Relypsa, Stealth, Peptide,Trevena, Z Pharma, and Zensun. He is also on the speakers bureau for Novartis. Additionally, he has received research grants from NIH and the European Union. |
HORIZON PLANNER DISCLOSURES
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following Horizon CME planners and managers, Brian Lee, PharmD, Cara Williams, PharmD, and Elizabeth Wilkerson hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Horizon CME planners and managers, Brian Lee, PharmD, Cara Williams, PharmD, and Elizabeth Wilkerson hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
SUPPORTER ACKNOWLEDGEMENT
This activity is supported by educational funding provided by Amgen.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
